← Patent-cliff monitor small molecule GOMEKLI MIRDAMETINIB
Loss of exclusivity October 2044 latest FDA-listed patent expiry
Company SPRINGWORKS THERAPEUTICS INC
Drug detail Brand name GOMEKLI Active ingredient MIRDAMETINIB Strength 4MG Dosage form TABLET, FOR SUSPENSION Route ORAL Modality Small molecule FDA approval July 2026 Marketing status RX
Listed patents Patent Expires Type 12390430 October 2044 use U-4130 12029711 March 2044 product 12661330 February 2044 use U-4130 12324791 March 2043 use U-4591 12220390 March 2043 use U-4130 12357597 February 2041 use U-4130 11453641 February 2041 use U-4130 11066358 February 2041 substance, product 11571402 February 2041 product 12295925 February 2041 use U-4590 11084780 February 2041 substance 12037306 February 2041 use U-4130 12263146 February 2041 use U-4130 11819487 February 2041 use U-4590 11806321 February 2041 use U-4130
Regulatory exclusivity Code Expires ODE* February 2032 NCE February 2030
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.